Two Sigma Advisers LP decreased its stake in Xencor, Inc. (NASDAQ:XNCR - Free Report) by 22.8% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 442,000 shares of the biopharmaceutical company's stock after selling 130,900 shares during the quarter. Two Sigma Advisers LP owned approximately 0.63% of Xencor worth $10,157,000 as of its most recent SEC filing.
A number of other hedge funds have also recently modified their holdings of the stock. RTW Investments LP boosted its position in Xencor by 317.9% during the fourth quarter. RTW Investments LP now owns 2,402,883 shares of the biopharmaceutical company's stock worth $55,218,000 after purchasing an additional 1,827,883 shares in the last quarter. BVF Inc. IL boosted its position in Xencor by 169.3% during the fourth quarter. BVF Inc. IL now owns 2,288,760 shares of the biopharmaceutical company's stock worth $52,596,000 after purchasing an additional 1,438,760 shares in the last quarter. Nuveen Asset Management LLC boosted its position in Xencor by 452.4% during the fourth quarter. Nuveen Asset Management LLC now owns 837,082 shares of the biopharmaceutical company's stock worth $19,236,000 after purchasing an additional 685,557 shares in the last quarter. Finepoint Capital LP purchased a new position in Xencor during the fourth quarter worth approximately $15,167,000. Finally, Vanguard Group Inc. boosted its position in Xencor by 5.5% during the fourth quarter. Vanguard Group Inc. now owns 8,017,366 shares of the biopharmaceutical company's stock worth $184,239,000 after purchasing an additional 418,040 shares in the last quarter.
Xencor Price Performance
Shares of NASDAQ:XNCR traded up $0.04 during midday trading on Wednesday, hitting $7.79. The company had a trading volume of 143,689 shares, compared to its average volume of 655,067. Xencor, Inc. has a twelve month low of $7.16 and a twelve month high of $27.24. The company has a debt-to-equity ratio of 0.01, a current ratio of 6.23 and a quick ratio of 6.23. The stock has a market cap of $554.42 million, a price-to-earnings ratio of -2.43 and a beta of 0.99. The business's 50-day simple moving average is $9.45 and its 200-day simple moving average is $16.48.
Xencor (NASDAQ:XNCR - Get Free Report) last posted its quarterly earnings results on Thursday, May 8th. The biopharmaceutical company reported ($0.66) EPS for the quarter, missing the consensus estimate of ($0.60) by ($0.06). Xencor had a negative net margin of 232.77% and a negative return on equity of 30.92%. The company had revenue of $32.73 million during the quarter, compared to analyst estimates of $23.44 million. During the same period in the prior year, the business posted ($1.11) EPS. Xencor's revenue for the quarter was up 104.6% compared to the same quarter last year. On average, research analysts predict that Xencor, Inc. will post -3.68 earnings per share for the current year.
Analyst Ratings Changes
A number of brokerages have issued reports on XNCR. Wall Street Zen downgraded Xencor from a "hold" rating to a "sell" rating in a research report on Friday, March 14th. Wedbush reiterated an "outperform" rating and set a $31.00 price target on shares of Xencor in a research report on Wednesday, April 30th. Barclays decreased their target price on Xencor from $22.00 to $6.00 and set an "underweight" rating on the stock in a research report on Thursday, May 8th. William Blair began coverage on Xencor in a research report on Monday, April 21st. They issued an "outperform" rating on the stock. Finally, Wells Fargo & Company decreased their target price on Xencor from $37.00 to $33.00 and set an "overweight" rating on the stock in a research report on Friday, February 28th. Two analysts have rated the stock with a sell rating, seven have issued a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat.com, Xencor presently has a consensus rating of "Moderate Buy" and a consensus price target of $29.50.
View Our Latest Research Report on XNCR
Insider Activity at Xencor
In related news, EVP Nancy Valente sold 4,616 shares of the stock in a transaction that occurred on Friday, May 2nd. The stock was sold at an average price of $11.03, for a total value of $50,914.48. Following the completion of the sale, the executive vice president now owns 49,169 shares of the company's stock, valued at approximately $542,334.07. This trade represents a 8.58% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 4.76% of the company's stock.
Xencor Profile
(
Free Report)
Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.
Further Reading
Before you consider Xencor, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Xencor wasn't on the list.
While Xencor currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
